Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Prostatic Neoplasms 2Small Cell Lung Carcinoma 1Recurrence 1Metastatic Castration-Resistant Prostate Cancer 1Lymphoma, Follicular 1Adenocarcinoma 1

Interventions

Carboplatin 11atezolizumab 10Etoposide 9durvalumab 6Topotecan 6PM 01183 6Specimen Handling 4pembrolizumab 3Magnetic Resonance Spectroscopy 3Irinotecan 2Injections 2Drug Therapy 2Cisplatin 2Biopsy 2AMG 757 2tremelimumab 1trastuzumab deruxtecan 1toripalimab 1olaparib 1lenvatinib 1fludarabine 1enzalutamide 1cabozantinib 1berzosertib 1avelumab 1arginine decarboxylase 1amrubicin 1Vaccines 1Taxes 1Sodium Chloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × PF06821497 × 30 days × Clear all
NCT03460977 2026-06-05

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

Phase 1 Recruiting
453 enrolled
LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡